Literature DB >> 18455323

Definitive radiotherapy for ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity.

Daniel J Indelicato1, Sameer R Keole, Amir H Shahlaee, Wenyin Shi, Christopher G Morris, Robert B Marcus.   

Abstract

PURPOSE: More than 70% of Ewing tumors occur in the extremities and pelvis. This study identified factors influencing local control and functional outcomes after management with definitive radiotherapy (RT). PATIENTS AND METHODS: A total of 75 patients with a localized Ewing tumor of the extremity or pelvis were treated with definitive RT at the University of Florida between 1970 and 2006 (lower extremity tumors in 30, pelvic tumors in 26, and upper extremity tumors in 19). RT was performed on a once-daily (40%) or twice-daily (60%) basis. The median dose was 55.2 Gy in 1.8-Gy daily fractions or 55.0 Gy in 1.2-Gy twice-daily fractions. The median observed follow-up was 4.7 years. Functional outcome was assessed using the Toronto Extremity Salvage Score.
RESULTS: The 10-year actuarial overall survival, cause-specific survival, freedom from relapse, and local control rate was 48%, 48%, 42%, and 71%, respectively. Of the 72 patients, 3 required salvage amputation. Inferior cause-specific survival was associated with larger tumors (81% for tumors <8 cm vs. 39% for tumors >/=8 cm, p <0.05). No patient characteristics or treatment variables were predictive of local failure. No fractures occurred in patients treated with hyperfractionation or with tumors of the distal extremities. Severe late complications were more frequently associated with use of <8-MV photons and fields encompassing the entire bone or hemipelvis. A significantly better Toronto Extremity Salvage Score was associated with a late-effect biologically effective dose of <91.7 Gy(3).
CONCLUSIONS: Limb preservation was effectively achieved through definitive RT. Treating limited field sizes with hyperfractionated high-energy RT could minimize long-term complications and provides superior functional outcomes.

Entities:  

Mesh:

Year:  2008        PMID: 18455323     DOI: 10.1016/j.ijrobp.2008.02.023

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

Review 1.  Progress in radiotherapy for pediatric sarcomas.

Authors:  Susan L McGovern; Anita Mahajan
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

2.  Targeted Molecular Radiotherapy of Pediatric Solid Tumors Using a Radioiodinated Alkyl-Phospholipid Ether Analog.

Authors:  Dana C Baiu; Ian R Marsh; Alexander E Boruch; Ankita Shahi; Saswati Bhattacharya; Justin J Jeffery; Qianqian Zhao; Lance T Hall; Jamey P Weichert; Bryan P Bednarz; Mario Otto
Journal:  J Nucl Med       Date:  2017-07-26       Impact factor: 10.057

3.  Treatment of Bone Tumors.

Authors:  Rajiv Rajani; C Parker Gibbs
Journal:  Surg Pathol Clin       Date:  2012-03

Review 4.  Radiation-related treatment effects across the age spectrum: differences and similarities or what the old and young can learn from each other.

Authors:  Matthew J Krasin; Louis S Constine; Debra L Friedman; Lawrence B Marks
Journal:  Semin Radiat Oncol       Date:  2010-01       Impact factor: 5.934

Review 5.  Ewing's sarcoma: standard and experimental treatment options.

Authors:  Vivek Subbiah; Pete Anderson; Alexander J Lazar; Emily Burdett; Kevin Raymond; Joseph A Ludwig
Journal:  Curr Treat Options Oncol       Date:  2009-06-17

6.  Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group.

Authors:  Safia K Ahmed; R Lor Randall; Steven G DuBois; William S Harmsen; Mark Krailo; Karen J Marcus; Katherine A Janeway; David S Geller; Joel I Sorger; Richard B Womer; Linda Granowetter; Holcombe E Grier; Richard G Gorlick; Nadia N I Laack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-08-24       Impact factor: 7.038

7.  Limited Margin Radiation Therapy for Children and Young Adults With Ewing Sarcoma Achieves High Rates of Local Tumor Control.

Authors:  Aimee C Talleur; Fariba Navid; Sheri L Spunt; M Beth McCarville; John Wu; Shenghua Mao; Andrew M Davidoff; Michael D Neel; Matthew J Krasin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-04-12       Impact factor: 7.038

8.  Role of Radiotherapy in the Multimodal Treatment of Ewing Sarcoma Family Tumors.

Authors:  Yunseon Choi; Do Hoon Lim; Soo Hyun Lee; Chuhl Joo Lyu; Jung Ho Im; Yun-Han Lee; Chang-Ok Suh
Journal:  Cancer Res Treat       Date:  2015-02-16       Impact factor: 4.679

9.  Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.

Authors:  Dimosthenis Andreou; Andreas Ranft; Georg Gosheger; Beate Timmermann; Ruth Ladenstein; Wolfgang Hartmann; Sebastian Bauer; Daniel Baumhoer; Henk van den Berg; P D Sander Dijkstra; Hans Roland Dürr; Hans Gelderblom; Jendrik Hardes; Lars Hjorth; Justus Kreyer; Jarmila Kruseova; Andreas Leithner; Sergiu Scobioala; Arne Streitbürger; Per-Ulf Tunn; Eva Wardelmann; Reinhard Windhager; Heribert Jürgens; Uta Dirksen
Journal:  Clin Orthop Relat Res       Date:  2020-02       Impact factor: 4.755

Review 10.  UK guidelines for the management of bone sarcomas.

Authors:  Craig Gerrand; Nick Athanasou; Bernadette Brennan; Robert Grimer; Ian Judson; Bruce Morland; David Peake; Beatrice Seddon; Jeremy Whelan
Journal:  Clin Sarcoma Res       Date:  2016-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.